MGI Pharma reports interim data

MOGN reported updated interim results from two ongoing Phase II trials of its irofulven acylfulvene

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE